Literature DB >> 8582473

The pharmacokinetics of granisetron, a 5-HT3 antagonist in healthy young and elderly volunteers.

A Allen, P Crome, C C Davie, M Davy, R W Jones, D M Pierce, J Upward, P Wijayawardhana.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582473     DOI: 10.1007/bf00194344

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects.

Authors:  A Allen; C C Asgill; D M Pierce; J Upward; B D Zussman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing.

Authors:  S E Clarke; N E Austin; J C Bloomer; R E Haddock; F C Higham; F J Hollis; M Nash; P C Shardlow; T C Tasker; F R Woods
Journal:  Xenobiotica       Date:  1994-11       Impact factor: 1.908

Review 5.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers.

Authors:  J F Pritchard; J C Bryson; A E Kernodle; T L Benedetti; J R Powell
Journal:  Clin Pharmacol Ther       Date:  1992-01       Impact factor: 6.875

7.  Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group.

Authors:  D Kamanabrou
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

8.  Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group.

Authors:  V Diehl
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

9.  A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.

Authors:  M Marty
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

10.  Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.

Authors:  J C Bloomer; S J Baldwin; G J Smith; A D Ayrton; S E Clarke; R J Chenery
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.